Surgery Partners, Inc. has made significant adjustments to its merger agreement with Spyglass Topco, LLC, aimed at enhancing shareholder value. The amendment, filed on November 9, 2026, increases the cash consideration for each share of the company’s common stock to $25.00. This strategic move is designed to attract and retain investor confidence amid a competitive landscape in the medical and surgical hospital services sector.

The amended agreement also introduces a ticking fee structure, which will provide additional monthly cash payments to shareholders if the merger is not completed by March 1, 2027. This fee is set at a rate of 10% per annum on the $25.00 per share merger consideration, potentially adding up to $1.61 per share by the maximum deadline of October 23, 2027.

Background

Surgery Partners, Inc. operates in the medical and surgical hospitals sector, specifically classified under SIC 8062, which encompasses services related to general medical and surgical hospitals. The company trades on the Nasdaq under the ticker symbol SGRY. Founded in Delaware, Surgery Partners has been actively involved in expanding its operations and enhancing its service offerings through strategic mergers and acquisitions.

What the Filing Says

The recent filing indicates that the amendment to the merger agreement aims to provide a more attractive offer for shareholders. It states, "The Amendment increases the merger consideration to be paid by Parent for each share of the Company Common Stock to $25.00 per share in cash." Additionally, it outlines the introduction of a ticking fee for shareholders if the merger is delayed.

Impact

This amendment could significantly affect Surgery Partners' shareholders by increasing the immediate cash value of their shares. Furthermore, the introduction of the ticking fee may motivate timely completion of the merger, ensuring that shareholders are compensated for any delays. The competitive landscape in the medical and surgical hospital services industry may prompt other companies to reassess their merger strategies and shareholder engagement approaches.

What's Next

The filing does not specify what happens next. However, it is expected that Surgery Partners will continue to engage with shareholders and regulatory bodies to facilitate the completion of the merger with Spyglass Topco, LLC.